Ipratropium bromide/salbutamol

Ipratropium bromide/salbutamol, sold under the brand name Combivent among others, is a combination medication used to treat chronic obstructive pulmonary disease (COPD).^[1][4][5] It contains ipratropium (an anticholinergic) and salbutamol (albuterol, a β₂-adrenergic agonist).^[1]

Ipratropium bromide/salbutamol

Combination of
Ipratropium bromide	Muscarinic antagonist
Salbutamol	Short-acting β2-adrenergic agonist
Clinical data
Trade names	Combivent, Duoneb, Breva, others
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a601063
License data	US DailyMed: Ipratropium bromide and albuterol
Routes of administration	Inhalation
ATC code	R03AK04 (WHO)
Legal status
Legal status	AU: S3 (Pharmacist only) UK: POM (Prescription only) US: ℞-only[1][2][3]
Identifiers
CAS Number	1031840-23-9
(verify)

Common side effects include sore throat, muscle cramps, and nausea.^[1] Other side effects may include bronchospasm, allergic reactions, and upper respiratory tract infections.^[1] Safety in pregnancy is unclear.^[6][1]

The combination was approved for medical use in the United States in 1996.^[7] It is available as a generic medication.^[4] In 2022, it was the 178th most commonly prescribed medication in the United States, with more than 2 million prescriptions.^[8][9]

Medical uses

Ipratropium bromide/salbutamol can be used for the treatment of COPD^[5] and asthma.^[10]

Society and culture

Since Combivent contains a chlorofluorocarbon-based propellant, its use was discontinued in 2013 in the United States and other countries. This is because chlorofluorocarbons are attributed to depletion of the ozone layer.^[11]